Le Lézard
Classified in: Health
Subjects: SVY, WOM

Nearly 3,000 Women Across America Reveal Surprising Lengths and Locations They've Had to Go to Answer Nature's Urgent Call


NORTHBROOK, Ill., Nov. 16, 2017 /PRNewswire/ -- Behind the bushes? In the men's room because the line for the women's restroom was too long? For women with symptoms of overactive bladder (OAB), these scenarios may not be imaginary. Dealing with OAB symptoms of urgency, frequency and leakage¹ can be difficult; talking about them even more so.² Approximately 46 million U.S. adults 40 years and older experience OAB symptoms at least sometimes3, yet only about 1 in 8 women actually seek treatment.4 Through its "Stop Stalling" campaign, Astellas encourages women to put aside their embarrassment and speak to their doctors about their bladder health.

Astellas is a pharmaceutical company dedicated to improving the health of people around the world. (PRNewsFoto/Astellas Pharma Inc.)

The second annual Peehavior survey, conducted by Astellas and Ipsos Public Affairs, asked 2,854 women across the United States about their bathroom experiences. Broaching the subject of urination can be awkward, but the women were surprisingly open about the places they'll "go."  The survey revealed that5:

"November is Bladder Health Month, so what better time to stop stalling and start a conversation about OAB symptoms than now?" said Ekene Enemchukwu, MD, MPH, a practicing urologist. "In my practice, I find women who think peeing frequently and urgently is just a natural part of aging, when in reality it may be signs of a condition that could be managed with a doctor's help."

Astellas created Stop Stalling® to educate, empower and motivate women to recognize OAB symptoms and take action by talking to their doctors. Since conversations about bladder health can be uncomfortable, the program incorporates subtle humor to break down barriers and get women talking.

The most recent addition to the Stop Stalling campaign is the "Stall Stories" video series, in which comedian Ellen Karis conducts light-hearted, yet informative, talk-show type interviews with experts in bladder and women's health. Representing various areas of expertise, the "guests" answer questions about OAB and seek to empower women to address their bladder health without feeling ashamed. They also discuss the importance of consulting a healthcare professional and provide tips on how to start what may feel like a difficult conversation.

For more information on OAB, visit StopStalling.com.

About Astellas
Astellas Pharma US, Inc. is a pharmaceutical company dedicated to improving the health of people around the world through the provision of innovative and reliable pharmaceutical products. For more information on Astellas, please visit our website at www.astellas.us. You can also follow us on Twitter at @AstellasUS, Facebook at www.facebook.com/AstellasUS or LinkedIn at www.linkedin.com/company/astellas-pharma.

References:

  1. Gormley EA, Lightner DJ, Burgio KL, et al. Diagnosis and treatment of overactive bladder (non-neurogenic) in adults: AUA/SUFU guideline. American Urological Association Education and Research, Inc. 2014.
  2. Filipetto FA., Fulda KG, Holthusen AE, McKeithen TM, McFadden P. The patient perspective on overactive bladder: a mixed-methods needs assessment. BMC Family Practice 2014;15:96-101.
  3. Coyne KS, Sexton CC, Vats V, Thompson C, Kopp ZS, Milsom I. National community prevalence of overactive bladder in the United States stratified by sex and age. Urology 2011;77(5):1081-7.
  4. Milsom I, Kaplan SA, Coyne KS, Sexton CC, Kopp ZS. Effect of bothersome overactive bladder symptoms on health-related quality of life, anxiety, depression, and treatment seeking in the United States: results from EpiLUTS. Urology 2012;80(1):90-6.
  5. Astellas and Ipsos Public Affairs. Data on File.

 

SOURCE Astellas Pharma Inc.


These press releases may also interest you

at 16:05
Arcturus Therapeutics Holdings Inc. (the "Company", "Arcturus", Nasdaq: ARCT), a global messenger RNA medicines company focused on the development of infectious disease vaccines and opportunities within liver and respiratory rare diseases, today...

at 16:05
Stevanato Group S.p.A. , a leading global provider of drug containment, drug delivery, and diagnostic solutions to the pharmaceutical, biotechnology, and life sciences industries, announced today that it will issue financial results for the first...

at 16:05
Bruker Corporation today announced it will report first quarter 2024 financial results before market opening on Thursday, May 2, 2024. The Company will host a conference call and webcast at 8:30 a.m. Eastern Time to discuss the results and current...

at 16:05
Gilead Sciences, Inc. announced today its first quarter 2024 results of operations. "Gilead delivered another strong quarter of revenue growth in the first quarter with 6% year-over-year growth in our base business driven by HIV, Oncology and...

at 16:05
DexCom, Inc. today reported its financial results as of and for the quarter ended March 31, 2024. First Quarter 2024 Financial Highlights: Revenue grew 24% year-over-year to $921.0 million on a reported basis and 25% year-over-year on an...

at 16:05
Ironwood Pharmaceuticals, Inc. today announced it will host its first quarter 2024 investor update conference call and webcast at 8:30 a.m. Eastern Time on Thursday, May 9, 2024. Individuals interested in participating in the call should dial (888)...



News published on and distributed by: